Market closed
Praxis Precision Medicines/$PRAX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Ticker
$PRAX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
82
Website
PRAX Metrics
BasicAdvanced
$1.4B
-
-$9.95
2.69
-
Price and volume
Market cap
$1.4B
Beta
2.69
52-week high
$91.83
52-week low
$33.01
Average daily volume
390K
Financial strength
Current ratio
13.595
Quick ratio
13.496
Long term debt to equity
0.434
Total debt to equity
0.434
Management effectiveness
Return on assets (TTM)
-39.20%
Return on equity (TTM)
-64.34%
Valuation
Price to revenue (TTM)
704.524
Price to book
3.46
Price to tangible book (TTM)
3.46
Price to free cash flow (TTM)
-11.359
Growth
Revenue change (TTM)
-16.93%
Earnings per share change (TTM)
-63.00%
3-year earnings per share growth (CAGR)
-42.41%
What the Analysts think about PRAX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
PRAX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PRAX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PRAX News
AllArticlesVideos
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Praxis Precision Medicines to Present at Two February Investor Conferences
GlobeNewsWire·3 weeks ago
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Praxis Precision Medicines stock?
Praxis Precision Medicines (PRAX) has a market cap of $1.4B as of February 24, 2025.
What is the P/E ratio for Praxis Precision Medicines stock?
The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of February 24, 2025.
Does Praxis Precision Medicines stock pay dividends?
No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next Praxis Precision Medicines dividend payment date?
Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) has a beta rating of 2.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.